



@article {3275,
	title = {Biodistribution and pharmacokinetics of Dapivirine-loaded nanoparticles after vaginal delivery in mice},
	journal = {Pharmaceutical Research},
	volume = {31},
	year = {2014},
	note = {Cited By (since 1996):2Export Date: 21 November 2014},
	month = {2014},
	pages = {1834 - 1845},
	abstract = {Purpose: To assess the potential of polymeric nanoparticles (NPs) to affect the genital distribution and local and systemic pharmacokinetics (PK) of the anti-HIV microbicide drug candidate dapivirine after vaginal delivery. Methods: Dapivirine-loaded, poly(ethylene oxide)-coated poly(epsilon-caprolactone) (PEO-PCL) NPs were prepared by a nanoprecipitation method. Genital distribution of NPs and their ability to modify the PK of dapivirine up to 24 h was assessed after vaginal instillation in a female mouse model. Also, the safety of NPs upon daily administration for 14 days was assessed by histological analysis and chemokine/cytokine content in vaginal lavages. Results: PEO-PCL NPs (180-200 nm) were rapidly eliminated after administration but able to distribute throughout the vagina and lower uterus, and capable of tackling mucus and penetrate the epithelial lining. Nanocarriers modified the PK of dapivirine, with higher drug levels being recovered from vaginal lavages and vaginal/lower uterine tissues as compared to a drug suspension. Systemic drug exposure was reduced when NPs were used. Also, NPs were shown safe upon administration for 14 days. Conclusions: Dapivirine-loaded PEO-PCL NPs were able to provide likely favorable genital drug levels, thus attesting the potential value of using this vaginal drug delivery nanosystem in the context of HIV prophylaxis. {\textcopyright} 2014 Springer Science+Business Media New York.},
	keywords = {HIV/AIDS, microbicides, poly(ε-caprolactone), pre-exposure prophylaxis, vaginal drug delivery},
	url = {http://www.scopus.com/inward/record.url?eid=2-s2.0-84904252215\&partnerID=40\&md5=e50091fa44bc3ac794251baa9e57d736},
	author = {Das Neves, J. and Ara{\'u}jo, F. and Andrade, F. and Amiji, M. and Bahia, M.F. and Sarmento, B.}
}
@article {3322,
	title = {Chitosan-modified porous silicon microparticles for enhanced permeability of insulin across intestinal cell monolayers},
	journal = {Biomaterials},
	volume = {35},
	year = {2014},
	note = {Cited By (since 1996):1Export Date: 21 November 2014},
	month = {2014},
	pages = {7172 - 7179},
	abstract = {Porous silicon (PSi) based particulate systems are emerging as an important drug delivery system due to its advantageous properties such as biocompatibility, biodegradability and ability to tailor the particles{\textquoteright} physicochemical properties. Here, annealed thermally hydrocarbonized PSi (AnnTHCPSi) and undecylenic acid modified AnnTHCPSi (AnnUnTHCPSi) microparticles were developed as a PSi-based platform for oral delivery of insulin. Chitosan (CS) was used to modify the AnnUnTHCPSi microparticles to enhance the intestinal permeation of insulin. Surface modification with CS led to significant increase in the interaction of PSi microparticles with Caco-2/HT-29 cell co-culture monolayers. Compared to pure insulin, the CS-conjugated microparticles significantly improved the permeation of insulin across the Caco-2/HT-29 cell monolayers, with ca. 20-fold increase in the amount of insulin permeated and ca. 7-fold increase in the apparent permeability (Papp) value. Moreover, among all the investigated particles, the CS-conjugated microparticles also showed the highest amount of insulin associated with the mucus layer and the intestinal Caco-2 cells and mucus secreting HT-29 cells. Our results demonstrate that CS-conjugated AnnUnTHCPSi microparticles can efficiently enhance the insulin absorption across intestinal cells, and thus, they are promising microsystems for the oral delivery of proteins and peptides across the intestinal cell membrane. {\textcopyright} 2014 Elsevier Ltd.},
	keywords = {Cell monolayers, chitosan, Diabetes, Insulin, Microparticles, Porous silicon},
	url = {http://www.scopus.com/inward/record.url?eid=2-s2.0-84902079022\&partnerID=40\&md5=4de20e5572512006f72e11cb61a2035c},
	author = {Shrestha, N. and Shahbazi, M.-A. and Ara{\'u}jo, F. and Zhang, H. and M{\"a}kil{\"a}, E.M. and Kauppila, J. and Sarmento, B. and Salonen, J.J. and Hirvonen, J.T. and Santos, H.A.}
}
@article {3264,
	title = {The impact of nanoparticles on the mucosal translocation and transport of GLP-1 across the intestinal epithelium},
	journal = {Biomaterials},
	volume = {35},
	year = {2014},
	note = {Export Date: 21 November 2014},
	month = {2014},
	pages = {9199 - 9207},
	abstract = {Glucagon like peptide-1 (GLP-1) is an incretin hormone that is in the pipeline for type 2 diabetes mellitus (T2DM) therapy. However, oral administration of GLP-1 is hindered by the harsh conditions of the gastrointestinal tract and poor bioavailability. In this study, three nanosystems composed by three different biomaterials (poly(lactide-co-glycolide) polymer (PLGA), Witepsol E85 lipid (solid lipid nanoparticles, SLN) and porous silicon (PSi) were developed and loaded with GLP-1 to study their permeability invitro. All the nanoparticles presented a size of approximately 200nm. The nanoparticles{\textquoteright} interaction with the mucus and the intestinal cells were enhanced after coating with chitosan (CS). PSi nanosystems presented the best association efficiency (AE) and loading degree (LD), even though a high AE was also observed for PLGA nanoparticles and SLN. Among all the nanosystems, PLGA and PSi were the only nanoparticles able to sustain the release of GLP-1 in biological fluids when coated with CS. This characteristic was also maintained when the nanosystems were in contact with the intestinal Caco-2 and HT29-MTX cell monolayers. The CS-coated PSi nanoparticles showed the highest GLP-1 permeation across the intestinal invitro models. In conclusion, PLGA+CS and PSi+CS are promising nanocarriers for the oral delivery of GLP-1. {\textcopyright} 2014 Elsevier Ltd.},
	keywords = {chitosan, Diabetes, Glucagon like peptide-1, nanoparticles, Oral delivery systems, Triple co-culture},
	url = {http://www.scopus.com/inward/record.url?eid=2-s2.0-84906788144\&partnerID=40\&md5=38c557a51eb271561ef59bfe12421842},
	author = {Ara{\'u}jo, F. and Shrestha, N. and Shahbazi, M.-A. and Fonte, P. and M{\"a}kil{\"a}, E.M. and Salonen, J.J. and Hirvonen, J.T. and Granja, P.L. and Santos, H.A. and Sarmento, B.}
}
@article {2873,
	title = {Establishment of a triple co-culture in vitro cell models to study intestinal absorption of peptide drugs},
	journal = {European Journal of Pharmaceutics and Biopharmaceutics},
	volume = {83},
	year = {2013},
	note = {Cited By (since 1996):4Export Date: 12 December 2013Source: Scopus},
	month = {2013///},
	pages = {427 - 435},
	url = {http://www.scopus.com/inward/record.url?eid=2-s2.0-84875219051\&partnerID=40\&md5=7e18e0b0ec3428fe07eee3fa109ba607},
	author = {Antunes, F. and Andrade, F. and Ara{\'u}jo, F. and Ferreira, D. and Sarmento, B.}
}
@article {2857,
	title = {In vitro and Ex Vivo evaluation of polymeric nanoparticles for vaginal and rectal delivery of the anti-HIV drug dapivirine},
	journal = {Molecular Pharmaceutics},
	volume = {10},
	year = {2013},
	note = {Cited By (since 1996):1Export Date: 12 December 2013Source: Scopus},
	month = {2013///},
	pages = {2793 - 2807},
	url = {http://www.scopus.com/inward/record.url?eid=2-s2.0-84879736868\&partnerID=40\&md5=cd7771212c94b7031331e338743b05ed},
	author = {Das Neves, J. and Ara{\'u}jo, F. and Andrade, F. and Michiels, J. and Ari{\"e}n, K.K. and Vanham, G. and Amiji, M. and Bahia, M.F. and Sarmento, B.}
}
@article {2841,
	title = {Towards the characterization of an in vitro triple co-culture intestine cell model for permeability studies},
	journal = {International Journal of Pharmaceutics},
	volume = {458},
	year = {2013},
	note = {Export Date: 12 December 2013Source: Scopus},
	month = {2013///},
	pages = {128 - 134},
	url = {http://www.scopus.com/inward/record.url?eid=2-s2.0-84888328477\&partnerID=40\&md5=08a91f0c4957ab3d8d2734e503d5a27c},
	author = {Ara{\'u}jo, F. and Sarmento, B.}
}
